Citius Oncology (CTOR) Competitors $1.69 -0.03 (-1.74%) Closing price 04:00 PM EasternExtended Trading$1.72 +0.03 (+1.48%) As of 07:53 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesOwnershipSEC FilingsTrendsBuy This Stock CTOR vs. MRVI, KROS, BCAX, RLAY, TYRA, SAGE, UPXI, TRML, TERN, and RAPPShould you be buying Citius Oncology stock or one of its competitors? The main competitors of Citius Oncology include Maravai LifeSciences (MRVI), Keros Therapeutics (KROS), Bicara Therapeutics (BCAX), Relay Therapeutics (RLAY), Tyra Biosciences (TYRA), Sage Therapeutics (SAGE), Upexi (UPXI), Tourmaline Bio (TRML), Terns Pharmaceuticals (TERN), and Rapport Therapeutics (RAPP). These companies are all part of the "pharmaceutical products" industry. Citius Oncology vs. Its Competitors Maravai LifeSciences Keros Therapeutics Bicara Therapeutics Relay Therapeutics Tyra Biosciences Sage Therapeutics Upexi Tourmaline Bio Terns Pharmaceuticals Rapport Therapeutics Citius Oncology (NASDAQ:CTOR) and Maravai LifeSciences (NASDAQ:MRVI) are both small-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their media sentiment, dividends, analyst recommendations, earnings, profitability, valuation, institutional ownership and risk. Which has more volatility & risk, CTOR or MRVI? Citius Oncology has a beta of 3, indicating that its share price is 200% more volatile than the S&P 500. Comparatively, Maravai LifeSciences has a beta of 0.28, indicating that its share price is 72% less volatile than the S&P 500. Which has preferable earnings & valuation, CTOR or MRVI? Citius Oncology has higher earnings, but lower revenue than Maravai LifeSciences. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioCitius OncologyN/AN/AN/AN/AN/AMaravai LifeSciences$259.18M2.56-$144.85M-$1.36-1.92 Is CTOR or MRVI more profitable? Citius Oncology has a net margin of 0.00% compared to Maravai LifeSciences' net margin of -90.03%. Maravai LifeSciences' return on equity of -17.60% beat Citius Oncology's return on equity.Company Net Margins Return on Equity Return on Assets Citius OncologyN/A -51.93% -22.17% Maravai LifeSciences -90.03%-17.60%-9.30% Does the media refer more to CTOR or MRVI? In the previous week, Maravai LifeSciences had 11 more articles in the media than Citius Oncology. MarketBeat recorded 17 mentions for Maravai LifeSciences and 6 mentions for Citius Oncology. Citius Oncology's average media sentiment score of 1.03 beat Maravai LifeSciences' score of -0.03 indicating that Citius Oncology is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Citius Oncology 1 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Maravai LifeSciences 2 Very Positive mention(s) 2 Positive mention(s) 6 Neutral mention(s) 3 Negative mention(s) 1 Very Negative mention(s) Neutral Do institutionals & insiders believe in CTOR or MRVI? 70.5% of Citius Oncology shares are owned by institutional investors. Comparatively, 50.3% of Maravai LifeSciences shares are owned by institutional investors. 4.6% of Citius Oncology shares are owned by company insiders. Comparatively, 2.1% of Maravai LifeSciences shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term. Do analysts prefer CTOR or MRVI? Citius Oncology presently has a consensus price target of $3.00, indicating a potential upside of 77.51%. Maravai LifeSciences has a consensus price target of $5.75, indicating a potential upside of 120.31%. Given Maravai LifeSciences' stronger consensus rating and higher probable upside, analysts plainly believe Maravai LifeSciences is more favorable than Citius Oncology.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Citius Oncology 0 Sell rating(s) 2 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 2.00Maravai LifeSciences 1 Sell rating(s) 7 Hold rating(s) 4 Buy rating(s) 0 Strong Buy rating(s) 2.25 SummaryMaravai LifeSciences beats Citius Oncology on 7 of the 12 factors compared between the two stocks. Get Citius Oncology News Delivered to You Automatically Sign up to receive the latest news and ratings for CTOR and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding CTOR and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart CTOR vs. The Competition Export to ExcelMetricCitius OncologyMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$132.45M$3.13B$5.68B$9.80BDividend YieldN/A2.23%4.59%4.07%P/E RatioN/A20.7930.6825.54Price / SalesN/A371.51463.80116.04Price / CashN/A43.0338.2159.48Price / Book4.128.638.996.13Net IncomeN/A-$54.65M$3.25B$264.89M7 Day Performance-6.63%6.59%4.76%2.66%1 Month Performance9.74%9.57%6.72%3.05%1 Year Performance-24.89%14.06%30.51%25.05% Citius Oncology Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)CTORCitius Oncology1.6599 of 5 stars$1.69-1.7%$3.00+77.5%-30.4%$132.45MN/A0.00N/ANews CoveragePositive NewsMRVIMaravai LifeSciences3.7034 of 5 stars$2.06-6.4%$6.64+222.3%-68.4%$560.25M$259.18M-1.81610Analyst ForecastKROSKeros Therapeutics2.4898 of 5 stars$13.35-2.8%$30.00+124.7%-66.8%$557.65M$3.55M43.07100BCAXBicara Therapeutics1.9782 of 5 stars$9.99-2.1%$31.86+218.9%N/A$556.27MN/A0.0032News CoverageEarnings ReportAnalyst ForecastAnalyst RevisionRLAYRelay Therapeutics1.9595 of 5 stars$3.25+0.9%$17.25+430.8%-47.4%$555.16M$10.01M-1.67330TYRATyra Biosciences2.3935 of 5 stars$10.10-3.3%$30.83+205.3%-50.4%$554.79MN/A-6.2020News CoverageEarnings ReportUpcoming EarningsGap UpSAGESage Therapeutics3.9326 of 5 stars$8.68flat$7.85-9.6%N/A$543.54M$41.24M-1.78690UPXIUpexi3.0176 of 5 stars$5.62-7.0%$15.50+175.8%+94.2%$539.74M$26M0.00130News CoverageAnalyst UpgradeShort Interest ↑TRMLTourmaline Bio2.571 of 5 stars$20.99+1.3%$49.33+135.0%+65.7%$532.20MN/A-6.5444News CoverageEarnings ReportAnalyst ForecastTERNTerns Pharmaceuticals4.0274 of 5 stars$6.30+3.6%$15.63+148.0%+4.3%$532.07MN/A-6.0640RAPPRapport Therapeutics1.7456 of 5 stars$14.34-1.4%$29.50+105.7%-26.8%$531.04MN/A-5.74N/AAnalyst Revision Related Companies and Tools Related Companies Maravai LifeSciences Competitors Keros Therapeutics Competitors Bicara Therapeutics Competitors Relay Therapeutics Competitors Tyra Biosciences Competitors Sage Therapeutics Competitors Upexi Competitors Tourmaline Bio Competitors Terns Pharmaceuticals Competitors Rapport Therapeutics Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:CTOR) was last updated on 8/15/2025 by MarketBeat.com Staff From Our PartnersTrump’s national nightmare is herePorter Stansberry and Jeff Brown say a new U.S. national emergency is already underway — and it could trigger ...Porter & Company | SponsoredAlex’s “Next Magnificent Seven” stocksThe original “Magnificent Seven” turned $7K into $1.18 million. Now, Alex Green has identified AI’s Next Ma...The Oxford Club | SponsoredThe Robotics Revolution has arrived … and one $7 stock could take off as a result.Something big is brewing in Washington. According to my research, an executive order from President Trump c...Weiss Ratings | SponsoredGENIUS Act: Cancel Your Money?A new law called the GENIUS Act could quietly trigger the most radical shift in American finance in decades. B...Priority Gold | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredBONUS GUIDE - Ben Stein Prepares For the Next Financial CrisisWith inflation high, debt soaring, and global tensions rising, a financial storm may be brewing. Economist ...Goldco Precious Metals | SponsoredElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | SponsoredTrump set to Boost Social Security Checks by 400%?If you're collecting or planning to collect social security... You should see this presentation about Presi...InvestorPlace | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Citius Oncology, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Citius Oncology With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
MarketBeat All Access